The impact of sharing results of a randomized breast cancer clinical trial with study participants Journal Article


Authors: Partridge, A. H.; Wolff, A. C.; Marcom, P. K.; Kaufman, P. A.; Zhang, L.; Gelman, R.; Moore, C.; Lake, D.; Fleming, G. F.; Rugo, H. S.; Atkins, J.; Sampson, E.; Collyar, D.; Winer, E. P.
Article Title: The impact of sharing results of a randomized breast cancer clinical trial with study participants
Abstract: Background There has been growing interest in providing clinical trial participants with study results yet only limited information exists regarding the process and impact of sharing results. We sought to evaluate patient perceptions of how results had been shared from a large randomized cooperative group trial, and the impact of learning results. Patients and methods A subset of women who participated in NCCTG 9831 (A Phase III Trial of Adjuvant Chemotherapy with or without Trastuzumab for Women with HER2-positive Breast Cancer) were mailed surveys after the preliminary study results were released to the public and mailed to participants. Results One hundred and 67 of 228 surveys sent (73%) were returned; 61% reported receiving trastuzumab on study; 4% reported recurrent disease. Ninety-five percent of participants were glad they received results; 81% were satisfied with how results were shared; 23% were more anxious after learning the results. Sixty-nine percent correctly interpreted the results. Logistic regression revealed that satisfaction with the process of receiving results was associated with satisfaction with treatment (P = 0.04), and increased anxiety was associated with dissatisfaction with treatment (0.02), incorrect interpretation of results (0.04), and not having received trastuzumab (P < 0.0001). Conclusion Sharing results directly with study participants is met with overwhelmingly favorable responses from patients, although some may not initially understand the findings. The potential for increased anxiety should be considered, and psychosocial support may be required by some. A plan to share results should be routinely and prospectively considered in the design of cancer clinical trials. © 2008 Springer Science+Business Media, LLC.
Keywords: adult; controlled study; aged; middle aged; patient satisfaction; major clinical study; clinical trial; cancer recurrence; doxorubicin; paclitaxel; chemotherapy, adjuvant; research design; controlled clinical trial; breast cancer; randomized controlled trial; patient education as topic; randomized controlled trials as topic; health survey; recurrence; cyclophosphamide; questionnaire; antibodies, monoclonal; data collection; clinical trials, phase iii as topic; communication; anxiety disorder; recurrent disease; anxiety; trastuzumab; regression analysis; logistic regression analysis; perception; adjuvant trastuzumab; cancer communication; clinical trial results; research ethics; postal mail
Journal Title: Breast Cancer Research and Treatment
Volume: 115
Issue: 1
ISSN: 0167-6806
Publisher: Springer  
Date Published: 2009-05-01
Start Page: 123
End Page: 129
Language: English
DOI: 10.1007/s10549-008-0057-7
PUBMED: 18543100
PROVIDER: scopus
DOI/URL:
Notes: --- - "Cited By (since 1996): 3" - "Export Date: 30 November 2010" - "CODEN: BCTRD" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Diana E Lake
    89 Lake